Welcome to the Pharmacokinetics Research Group

Welcome to the Pharmacokinetics Research Group

Pharmacokinetics is the quantitative assessment of what the body does to a chemical following exposure. The fate of a chemical in a living organism is a function of its physicochemical properties as well as the anatomy and physiology of the organism. Four main concepts form the basis for describing the rate and extent of exposure - Absorption, Distribution, Metabolism and Excretion, or ADME for short.

Our research is focused on building virtual organisms to study the pharmacokinetics of drugs, novel molecules and environmental contaminants. Physiologically-based pharmacokinetic (PBPK) models offer a mechanistic approach to understanding how changes in anatomy and physiology can affect the ADME of a chemical. PBPK models are predictive and can be used to scale pharmacokinetics across species (e.g., rat to human) and within a species (e.g., healthy adult humans to children or patients) with an eye towards determining the right dose (in medicine) or determining differential risks associated with contaminant exposure (in human health risk assessment).

Our research extends to different modeling methods with a focus in bleeding disorders. The lab is the population pharmacokinetic modelling lead within the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo.org) program. Initiated out of McMaster University by Dr. Alfonso Iorio, WAPPS-Hemo offers hemophilia treaters a platform that employs established brand-specific population pharmacokinetic (PK) models using Bayesian forecasting. By incorporating patient covariates and factor concentrate plasma levels, it generates personalized PK estimates to optimize individualized dosing.  We have 800+ clinical sites using the WAPPS-Hemo service from 50+ countries.  The WAPPS-Hemo platform is currently the largest repository of real-world data and population PK models on hemophilia, continuously gathering information that supports research efforts to advance hemophilia treatment globally.

 In all our research, we collaborate with global partners and are most interested in the development of models and tools for optimal medication dosing as well as human health risk assessment.


Students interested in graduate studies at either the M.Sc. or Ph.D. level with interests or experience in the following areas can email me directly:  aedginto@uwaterloo.ca

  • PBPK modeling
  • Pediatric PBPK modeling
  • Pharmacokinetic and pharmacodynamic (PK/PD) modeling

  • Model Informed Precision Dosing (MIPD)
  • Quantitative Systems Pharmacology (QSP)

I am particularly interested in students who possess strong mathematical and/or statistical skills as well as health professionals.

Meet our people

Dr. Andrea Edginton

Professor; Hallman Director; Associate Dean, Faculty of Science

Dr. Edginton’s research focuses on improving the confidence of physiologically-based pharmacokinetic (PBPK) model outcomes through understanding model inputs and developing modeling workflows.

News

Interview with Contemporary OB/GYN, Shirley Wang, a PhD student in the School of Pharmacy at the University of Waterloo, discussed the risks associated with breastfeeding while a mother is taking medication, focusing specifically on the drug Levetiracetam.

To hear the interview, click here

Congratulations to Shirley on her abstract: ADVANCEMENTS IN PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF DRUGS IN LACTATION FOR GUIDING NEONATAL EXPOSURE RISK ASSESSMENT”, that has been accepted for presentation and selected to receive a Presidential Trainee Award at the ASCPT 2025 Annual Meeting to be held May 28-30, 2025, at the Gaylord National in Washington, DC!

So proud of you Shirley!